Jyong Biotech Signs Letter of Intent for MCS-2 Licensing in South Korea
核心洞察
Jyong Biotech Ltd. (搜索) has entered into a non-binding letter of intent with a South Korean pharmaceutical company to evaluate in-licensing of its plant-derived drug candidate MCS-2 for the Korean market.
The partnership aims to leverage the Korean company's established commercial infrastructure and local regulatory expertise to accelerate market access for MCS-2, which specializes in treating urinary system diseases (搜索).
MCS-2 remains an investigational new drug candidate that has not been approved for commercial use in any jurisdiction, with definitive terms still under negotiation.
Taiwan-based biotechnology company Jyong Biotech Ltd. (搜索) (Nasdaq: MENS) announced on November 24, 2025, that it has entered into a non-binding letter of intent with a leading South Korean pharmaceutical company to evaluate the potential in-licensing and development of its plant-derived drug candidate MCS-2 for the Korean market. The prospective Korean partner is described as a recognized supplier to both general hospitals and clinics.
Strategic Partnership for Market Expansion
The letter of intent reflects mutual interest in assessing commercial and regulatory pathways for introducing MCS products in Korea. This engagement aligns with Jyong Biotech's co-commercialization strategy to collaborate with regional partners that offer established sales networks and local regulatory expertise.
The partnership, if definitive terms are agreed upon, would aim to leverage the Korean partner's commercial infrastructure to accelerate market access and patient reach in Korea. The LOI is non-exclusive and subject to customary due diligence, regulatory review, negotiation of definitive agreements, and other closing conditions.
Company Leadership Perspective
Fu Feng Kuo, Chairwoman of Jyong Biotech, commented on the strategic approach: "A selective co-commercialization approach with strategic partners will enable broader and faster patient access by combining its product development capabilities with partners' commercial scale and local market knowledge. The Company will work to advance LOI negotiation with these strategic partners and provide updates as material developments occur."
Drug Development Status
MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. The plant-derived drug is part of Jyong Biotech's focus on developing treatments for urinary system diseases (搜索). Jyong Biotech has committed to complying with applicable regulatory disclosure obligations and providing timely, accurate, and complete updates on material developments.
Company Background
Headquartered in Taiwan, Jyong Biotech Ltd. (搜索) is a science-driven biotechnology company committed to developing and commercializing innovative plant-derived drugs, mainly specializing in the treatment of urinary system diseases (搜索). The company focuses initially on the markets of the U.S., the EU, and Asia.
Since its inception in 2002, the company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the company has been developing a series of botanical drug candidates, including its primary botanical drug candidate BOTRESO (搜索)®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates.